Literature DB >> 26889760

Color polymorphs of aldose reductase inhibitor epalrestat: configurational, conformational and synthon differences.

Battini Swapna1, Kuthuru Suresh1, Ashwini Nangia1.   

Abstract

We report five crystalline polymorphs and an amorphous phase of epalrestat together with configurational isomerism and color behavior: form I (deep red), form II (deep orange), form III (bright yellow), form IV (yellow), and form V (orange) are in the E,Z configuration of the drug, and a Z,Z isomer (bright yellow). Two pathways are identified for polymorph conversion: direct transformation of the E,Z isomer and another pathway via the Z,Z isomer to the E,Z polymorphs. From a pharmaceutical perspective, the stability of polymorphs was established under grinding, solvent slurry and thermal conditions: form I (thermodynamic) > form II > form V > form III > form IV (least stable).

Entities:  

Year:  2016        PMID: 26889760     DOI: 10.1039/c6cc00697c

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN: 1359-7345            Impact factor:   6.222


  3 in total

1.  A new solvate of epalerstat, a drug for diabetic neuropathy.

Authors:  Okky Dwichandra Putra; Daiki Umeda; Kaori Fukuzawa; Mihoko Gunji; Etsuo Yonemochi
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2017-07-28

2.  Epalrestat tetra-hydro-furan monosolvate: crystal structure and phase transition.

Authors:  Daiki Umeda; Okky Dwichandra Putra; Mihoko Gunji; Kaori Fukuzawa; Etsuo Yonemochi
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2017-06-02

3.  Thermomechanical effect in molecular crystals: the role of halogen-bonding interactions.

Authors:  Sudhir Mittapalli; D Sravanakumar Perumalla; Jagadeesh Babu Nanubolu; Ashwini Nangia
Journal:  IUCrJ       Date:  2017-10-27       Impact factor: 4.769

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.